Rezultati - Ursula A. Matulonis

Refine Results
  1. 1
    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential

    PARP inhibitors in ovarian cancer: evidence, experience and clinical potential od Tarra Evans, Ursula A. Matulonis

    Izdano 2017
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?

    PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? od Ursula A. Matulonis, Bradley J. Monk

    Izdano 2017
    Polni tekst Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

    PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies od Elizabeth K. Lee, Ursula A. Matulonis

    Izdano 2020
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations

    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations od Jennifer Veneris, Ursula A. Matulonis, Joyce F. Liu, Panagiotis A. Konstantinopoulos

    Izdano 2019
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers

    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers od Elizabeth K. Lee, David L. Kolin, Ursula A. Matulonis, Britt Erickson

    Izdano 2025
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

    Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials od Ursula A. Matulonis, Amit M. Oza, Tony W. Ho, Jonathan A. Ledermann

    Izdano 2014
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies

    Biomarkers of Response and Resistance to DNA Repair Targeted Therapies od Elizabeth H. Stover, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Elizabeth M. Swisher

    Izdano 2016
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

    Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer od S. Percy Ivy, Joyce F. Liu, Jung‐Min Lee, Ursula A. Matulonis, Elise C. Kohn

    Izdano 2016
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines

    Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines od Brian J. Druker, Keiko Okuda, Ursula A. Matulonis, Ravi Salgia, Thomas M. Roberts, JD Griffin

    Izdano 1992
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

    Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor od Emily Robinson, Ursula A. Matulonis, Percy Ivy, Suzanne Berlin, Karin Tyburski, Richard T. Penson, Benjamin D. Humphreys

    Izdano 2010
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Ovarian cancer

    Ovarian cancer od Ursula A. Matulonis, Anil K. Sood, Lesley Fallowfield, Brooke E. Howitt, Jalid Sehouli, Beth Y. Karlan

    Izdano 2016
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.

    B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. od Ursula A. Matulonis, Chrysoula Dosiou, GJ Freeman, Christine Lamont, Peter Mauch, L M Nadler, James D. Griffin

    Izdano 1996
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma

    Targeted Next-Generation Sequencing Reveals Clinically Actionable <i>BRAF</i> and <i>ESR1</i> Mutations in Low-Grade Serous Ovarian Carcinoma od Elizabeth H. Stover, Colleen M. Feltmate, Ross S. Berkowitz, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health

    Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental Health od Alexi A. Wright, Nancy L. Keating, Tracy A. Balboni, Ursula A. Matulonis, Susan D. Block, Holly G. Prigerson

    Izdano 2010
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study

    Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study od Melissa A. Merritt, Megan S. Rice, Mollie E. Barnard, Susan E. Hankinson, Ursula A. Matulonis, Elizabeth M. Poole, Shelley S. Tworoger

    Izdano 2018
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

    Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks od Kun‐Hsing Yu, Vincent J. Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

    Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine od Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O’Malley, Ursula A. Matulonis, Gottfried E. Konecny

    Izdano 2023
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer

    TP006/#1423 Addchemo CC trial – adjuvant treatment in plasma HPV-DNA positive patients: a biomarker for chemotherapy in locally advanced cervical cancer od Michelle Samora, José Eduardo Levi, Sergio Nicolau, Edvane De Domenico, Ursula A. Matulonis, Audrey Tieko Tsunoda, Pâmela Perez Leite, Rafael Schmerling

    Izdano 2022
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance

    A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance od Raphaël Ceccaldi, Kevin W. O’Connor, Kent W. Mouw, Adam Y. Li, Ursula A. Matulonis, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos

    Izdano 2015
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

    Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells od Young Eun Choi, Chiara Battelli, Jacqueline Watson, Joyce F. Liu, Jennifer Curtis, Alexander Morse, Ursula A. Matulonis, Dipanjan Chowdhury, Panagiotis A. Konstantinopoulos

    Izdano 2014
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: